Bioxytran (BIXT) Enterprise Value (QoQ) (2013 - 2026)
Bioxytran (BIXT) Enterprise Value (QoQ) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.19% |
| Dec 31, 2025 | -3,416.89% |
| Sep 30, 2025 | -361.16% |
| Jun 30, 2025 | 27.69% |
| Mar 31, 2025 | 15.64% |
| Dec 31, 2024 | 85.13% |
| Sep 30, 2024 | 95.10% |
| Jun 30, 2024 | -0.50% |
| Mar 31, 2024 | 0.39% |
| Dec 31, 2023 | 4.38% |
| Sep 30, 2023 | -10.44% |
| Jun 30, 2023 | 13.88% |
| Mar 31, 2023 | 12.27% |
| Dec 31, 2022 | 3.03% |
| Sep 30, 2022 | -82.50% |
| Jun 30, 2022 | 57.85% |
| Mar 31, 2022 | -152.96% |
| Dec 31, 2021 | -166.29% |
| Sep 30, 2021 | 1.36% |
| Jun 30, 2021 | -35.98% |